Ipsen and Sutro Biopharma form global licensing deal for an ADC targeting solid tumors

The Directors: Tom Lynch and Skip Burris on how NIH funding cuts imperil biopharma innovation—and cost patient lives
In a time of uncertainty, “react to the knowns, not the fear”

Thomas J. Lynch Jr. and Howard A. “Skip” Burris III lead two institutions that couldn’t be more different—an NCI-designated Comprehensive Cancer Center on one side of the country and a for-profit research enterprise on the other—but they stay up at nights worrying about the same thing.

UChicago study reveals high doses of radiation can cause growth in existing metastatic tumors

Researchers at the University of Chicago Medicine Comprehensive Cancer Center have discovered that high doses of radiation cause growth in existing metastatic tumors that weren’t directly treated with radiation.

May 16, 2025

Vol.51 No.19

Clinical

TIL + pembro regimen achieves 24% response rate in solid epithelial tumors, marking a step forward in immunotherapy research

Immunotherapy has changed the course of blood cancers and melanomas, but is stubbornly ineffective for the treatment of most epithelial solid cancers—the cancers that kill about 90% of the more than 600,000 Americans who die of cancer each year.

FDA approves Vitrakvi for NTRK gene fusion-positive solid tumors

FDA granted full approval for Vitrakvi (larotrectinib), a first-in-class TRK inhibitor for the treatment of adult and pediatric patients with solid tumors that have a neurotrophic receptor tyrosine kinase gene fusion without a known acquired resistance mutation, are metastatic or where surgical resection is likely to result in severe morbidity, and have no satisfactory alternative treatments or that have progressed following treatment.

April 11, 2025

Vol.51 No.14

Drugs & Targets

FDA approves prostate cancer imaging agent Gozellix

FDA approved Gozellix (TLX007-CDx, kit for the preparation of gallium-68 (68Ga) gozetotide injection), a next-generation PSMA-PET imaging agent for prostate cancer.

March 28, 2025

Vol.51 No.12

In Brief

UCLA’s Theodore Scott Nowicki awarded $4.5M to advance cellular immunotherapies for solid tumors

Physician-scientist Theodore Scott Nowicki, an assistant professor-in-residence of pediatric hematology/oncology and microbiology, immunology, and molecular genetics at the David Geffen School of Medicine at UCLA, has been awarded a $4.5 million R37 MERIT Award to help improve the effectiveness of cellular therapies for solid tumors.

March 21, 2025

Vol.51 No.11

Ipsen and Sutro Biopharma form global licensing deal for an ADC targeting solid tumors

YOU MAY BE INTERESTED IN

The Directors: Tom Lynch and Skip Burris on how NIH funding cuts imperil biopharma innovation—and cost patient lives
In a time of uncertainty, “react to the knowns, not the fear”

UChicago study reveals high doses of radiation can cause growth in existing metastatic tumors

TIL + pembro regimen achieves 24% response rate in solid epithelial tumors, marking a step forward in immunotherapy research

FDA approves Vitrakvi for NTRK gene fusion-positive solid tumors

FDA approves prostate cancer imaging agent Gozellix

UCLA’s Theodore Scott Nowicki awarded $4.5M to advance cellular immunotherapies for solid tumors

Renew today!

Subscriber content

Never miss an issue!

Login

Ipsen and Sutro Biopharma form global licensing deal for an ADC targeting solid tumors

YOU MAY BE INTERESTED IN

The Directors: Tom Lynch and Skip Burris on how NIH funding cuts imperil biopharma innovation—and cost patient livesIn a time of uncertainty, “react to the knowns, not the fear”

UChicago study reveals high doses of radiation can cause growth in existing metastatic tumors

TIL + pembro regimen achieves 24% response rate in solid epithelial tumors, marking a step forward in immunotherapy research

FDA approves Vitrakvi for NTRK gene fusion-positive solid tumors

FDA approves prostate cancer imaging agent Gozellix

UCLA’s Theodore Scott Nowicki awarded $4.5M to advance cellular immunotherapies for solid tumors

Never miss an issue!

Login

The Directors: Tom Lynch and Skip Burris on how NIH funding cuts imperil biopharma innovation—and cost patient lives
In a time of uncertainty, “react to the knowns, not the fear”